FIXX [NASD]
Homology Medicines, Inc.
Index- P/E- EPS (ttm)-0.09 Insider Own9.15% Shs Outstand57.45M Perf Week-2.58%
Market Cap96.47M Forward P/E- EPS next Y-1.88 Insider Trans0.00% Shs Float52.23M Perf Month2.72%
Income-4.30M PEG- EPS next Q-0.51 Inst Own51.50% Short Float / Ratio2.04% / 5.43 Perf Quarter-30.73%
Sales3.20M P/S30.15 EPS this Y38.20% Inst Trans-4.10% Short Interest1.07M Perf Half Y-14.20%
Book/sh3.64 P/B0.41 EPS next Y-1314.30% ROA-1.60% Target Price8.14 Perf Year-68.87%
Cash/sh3.15 P/C0.48 EPS next 5Y-9.40% ROE-1.90% 52W Range1.30 - 5.14 Perf YTD-58.52%
Dividend- P/FCF- EPS past 5Y-50.70% ROI-56.50% 52W High-70.65% Beta-0.16
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin- 52W Low16.15% ATR0.15
Employees224 Current Ratio8.40 Sales Q/Q-52.90% Oper. Margin-36.50% RSI (14)46.33 Volatility9.42% 10.87%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.50% Profit Margin- Rel Volume0.51 Prev Close1.50
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume196.35K Price1.51
Recom2.10 SMA20-5.18% SMA50-1.68% SMA200-29.52% Volume100,118 Change0.67%
Feb-22-22Reiterated BTIG Research Neutral $35 → $29
Feb-22-22Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-22-22Downgrade Oppenheimer Outperform → Perform
Mar-02-21Initiated Stifel Hold $14
Dec-14-20Resumed H.C. Wainwright Buy $30
Aug-11-20Reiterated H.C. Wainwright Buy $37 → $30
Jun-25-20Resumed BofA/Merrill Buy $30
May-13-20Initiated RBC Capital Mkts Outperform $30
Mar-16-20Upgrade Oppenheimer Perform → Outperform $32
Feb-24-20Initiated Chardan Capital Markets Buy $34
Show Previous Ratings
Nov-12-22 08:08AM
Nov-10-22 05:45PM
04:07PM
Oct-27-22 09:00AM
Oct-06-22 08:30AM
08:15AM Loading…
Sep-27-22 08:15AM
Sep-08-22 11:05AM
Sep-06-22 04:01PM
Aug-17-22 01:05PM
Aug-16-22 11:52AM
Aug-15-22 06:15PM
04:10PM
Aug-12-22 07:46AM
Aug-11-22 04:05PM
Jul-25-22 09:12AM
08:30AM Loading…
Jul-05-22 08:30AM
Jun-29-22 08:00AM
Jun-13-22 08:00AM
Jun-10-22 08:30AM
May-18-22 06:00AM
May-16-22 06:05PM
04:15PM
May-13-22 08:45AM
May-02-22 04:56PM
Apr-21-22 08:30AM
Mar-23-22 05:45PM
04:10PM
Mar-10-22 04:01PM
Mar-08-22 10:00AM
Mar-07-22 09:38AM
03:00PM Loading…
Mar-03-22 03:00PM
07:30AM
Feb-24-22 08:45AM
05:39AM
Feb-23-22 10:00AM
Feb-22-22 07:34AM
Feb-21-22 09:40AM
02:53AM
Feb-18-22 04:05PM
Feb-10-22 11:40AM
07:18AM
Feb-02-22 09:40AM
Jan-28-22 10:46AM
02:30AM
Jan-21-22 09:38AM
Dec-12-21 08:19AM
Dec-10-21 06:38PM
Nov-15-21 07:10AM
Nov-03-21 08:29AM
Nov-01-21 03:01PM
Oct-21-21 07:00AM
Oct-20-21 08:30AM
Oct-18-21 08:30AM
Oct-13-21 08:21AM
Oct-12-21 04:05PM
Oct-11-21 08:39AM
Aug-14-21 03:27AM
Aug-12-21 07:05PM
04:05PM
Aug-05-21 08:30AM
Aug-04-21 08:30AM
Aug-02-21 03:01PM
Jun-19-21 05:23AM
May-13-21 07:00AM
May-06-21 06:15PM
04:05PM
May-03-21 08:00AM
Apr-29-21 05:06PM
Apr-28-21 08:00AM
Apr-20-21 03:28AM
Apr-14-21 08:30AM
Apr-12-21 08:30AM
Apr-07-21 12:15PM
08:52AM
Apr-06-21 04:19PM
Mar-22-21 08:00AM
Mar-11-21 07:05PM
04:10PM
Mar-04-21 12:30PM
Mar-01-21 09:51AM
07:30AM
Feb-25-21 08:00AM
Feb-19-21 02:30AM
Feb-08-21 02:50PM
Jan-06-21 08:00AM
Dec-14-20 01:36PM
Dec-11-20 07:05PM
02:15PM
Nov-25-20 10:36AM
Nov-10-20 03:05PM
Nov-09-20 07:00PM
05:35PM
04:05PM
08:00AM
Nov-08-20 09:56AM
Nov-06-20 11:40AM
Nov-05-20 09:15AM
Nov-03-20 12:30PM
Oct-29-20 06:50PM
Oct-28-20 07:45PM
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cohn GabrielChief Medical OfficerJan 05Sale3.781,6616,2792,629Jan 12 04:05 PM
Seymour AlbertChief Scientific OfficerJan 05Sale3.781,6616,279131,646Jan 12 04:05 PM
Kelly Timothy PChief Operating OfficerJan 05Sale3.781,4065,3152,224Jan 12 04:05 PM
Smith W BradfordCFO & TreasurerJan 05Sale3.782,1828,2484,418Jan 12 04:05 PM
TZIANABOS ARTHURPresident & CEOJan 05Sale3.785,35420,23986,011Jan 12 04:05 PM